Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 2, pp 260–267 | Cite as

The use of pharmaceutical care to improve health-related quality of life in hemodialysis patients in Iran

  • Simin Dashti-KhavidakiEmail author
  • Zahra Sharif
  • Hossein Khalili
  • Shirinsadat Badri
  • Abbas Alimadadi
  • Farrokhlegha Ahmadi
  • Mansoor Gatmiri
  • Soraya Rahimzadeh
Research Article

Abstract

Background Compared with the general population, hemodialysis patients suffer from worse health-related quality of life (HRQoL). Poor HRQoL results in the higher risk of hospitalization and mortality. Objective This study was designed to assess the impact of pharmaceutical care on HRQoL of hemodialysis patients. Setting This study was performed in a university hemodialysis center in Iran. Methods At the initiation of the study HRQoL of dialysis patients were assessed using SF-36 instrument and patients’ demographic and laboratory data were gathered. Hemodialysis patients were randomized to receive either only standard care of the ward consisted of brief medication review by nurses and monthly visits by nephrology fellow and attending physicians as the control group or receive clinical pharmacist-led pharmaceutical care in addition to the standard care of the ward as the case group. Finally patients’ HRQoL were assessed at the end of the month six of the study in both groups. Main Outcome Measure Quality of life as measured with the SF-36 was compared between case and control groups and within each group at the initiation and at the end of 6 months study. Results During this study, median (IQR) of HRQoL improved significantly from 56.9 (37.7–71.7) at the initiation of the study to 72.2 (55.3–83.7) at the end of the study in the case group (P = 0.001) especially in the role-emotional [from 66.6 (33.3–66.6) to 100.0 (100.0–100.0); P = 0.001], mental health [from 54.2 (40.8–73.5) to 68.3 (58.9–90.2); P = 0.007], social functioning [from 73.6 (37.5–100.0) to 93.4 (75.0–100.0); P = 0.01], and general health [from 45.0 (30.0–70.0) to 65.0 (48.8–75.0); P = 0.001] dimensions. Conversely, HRQoL did not change or decreased in the control group. This decrease was statistically significant in the general health domain [from 47.5 (33.8–56.3) to 40.0 (23.7–51.2); P = 0.04]. Conclusion Providing pharmaceutical care significantly improved HRQoL of hemodialysis patients especially in the role-emotional, mental health, social functioning, and general health dimensions.

Keywords

Clinical pharmacist Health-related quality of life Hemodialysis Iran Pharmaceutical care 

Notes

Acknowledgments

The authors appreciate the help of Dr Mohsen Rezaie-Hemami for the data analysis.

Funding

This study was part of a Pharm. D thesis supported by Tehran University of Medical Sciences.

Conflicts of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Mahdavi Mazdeh M, Heidary Rouchi A, Norouzi S, Aghighi M, Rajolani H, Ahrabi S. Renal replacement therapy in Iran. Urol J. 2007;4:66–70.PubMedGoogle Scholar
  2. 2.
    Cleary J, Drennan J. Quality of life of patients on haemodialysis for end-stage renal disease. J Adv Nurs. 2005;51(6):577–86.PubMedCrossRefGoogle Scholar
  3. 3.
    Walter BA, Hays RD, Spritzer KL, Fridman M, Carter WB. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis. 2002;40:1185–94.CrossRefGoogle Scholar
  4. 4.
    Loose C, Briancon S, Frimat L, Hanesse B, Kessler M. Effect of end-stage renal disease on the quality of life of older patients. J Am Geriatr Soc. 2003;51(2):229–33.CrossRefGoogle Scholar
  5. 5.
    Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, et al. Health-related quality of life and associated out-comes among hemodialysis patients of different ethnicities in the United States; the Dialysis outcome and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2003;41:605–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.PubMedGoogle Scholar
  7. 7.
    Thomas D, Joseph J, Francis B, Mohanta GP. Effect of patient counseling on quality of life of hemodialysis patients in India. Pharm Pract. 2009;7(3):181–4.Google Scholar
  8. 8.
    Pai AB, Boyd A, Chavez A, Manley HJ. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study. Hemodial Int. 2009;13:72–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Khier N, Foppe van Mil JW, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care targeting on outcome that matters. Pharm World Sci 2004; 26:125–8.Google Scholar
  10. 10.
    Manely HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, et al. Medication prescribing patterns in ambulatory hemodialysis patients: comparison of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19:1842–8.CrossRefGoogle Scholar
  11. 11.
    McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumption, and reliability across diverse patient group. Med Care. 1994;32:40–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Kring DL, Crane PB. Factors affecting quality of life in persons on hemodialysis. Nephrol Nurs J. 2009;36(1):15–55.PubMedGoogle Scholar
  13. 13.
    Salek SS. Quality of life in patients with end-stage renal disease. J Appl Therap. 1999;2:163–70.Google Scholar
  14. 14.
    Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, et al. Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res. 2007;16:545–57.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF-36 quality of life measures and nutrition, hospitalization and mortality in hemodialysis. J Am Soc Nephrol. 2001;12:2797–806.PubMedGoogle Scholar
  16. 16.
    Campbell KL, Ash S, Bauer JD. The impact of nutrition intervention on quality of life in pre-dialysis stage 4 and 5 of chronic kidney disease patients. Clin Nutr. 2008;27:537–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Landreneau K, Lee K, Landreneau MD. Quality of life in patients undergoing hemodialysis and renal transplantation—a meta-analytic review. Nephrol Nurs J. 2010;37(1):37–43.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Simin Dashti-Khavidaki
    • 1
    • 2
    Email author
  • Zahra Sharif
    • 3
  • Hossein Khalili
    • 1
  • Shirinsadat Badri
    • 4
  • Abbas Alimadadi
    • 5
  • Farrokhlegha Ahmadi
    • 2
  • Mansoor Gatmiri
    • 2
  • Soraya Rahimzadeh
    • 6
  1. 1.Department of Clinical Pharmacy, Faculty of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Nephrology Research CenterTehran University of Medical SciencesTehranIran
  3. 3.Faculty of PharmacyTehran University of Medical SciencesTehranIran
  4. 4.Faculty of PharmacyIsfahan University of Medical SciencesIsfahanIran
  5. 5.Tehran University of Medical SciencesTehranIran
  6. 6.Imam Khomeini Hospital ComplexTehran University of Medical SciencesTehranIran

Personalised recommendations